See the latest news and media coverage for Diamyd Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage diabetes therapy developer
diamyd.comLast updated
In short: Diamyd Medical terminated its Phase 3 DIAGNODE-3 trial following a futility analysis, prompting a CEO change and a strategic review.
The interim analysis of 174 participants did not show statistical significance, and no safety issues were identified. The company conducted a structured review that identified several factors for future studies.
He wrote an unusually candid letter in the Q3 report about stepping in as CEO during a crossroads.
Mathias Skalmstad takes up the position as CFO on July 1, 2026. He has experience from listed companies and life science.
Net sales 0.4 MSEK and net loss -238.8 MSEK. DIAGNODE-3 study discontinued due to lack of efficacy.
Review identifies potential contributing factors and informs future development considerations; no new safety concerns identified. The pre-specified interim analysis included 174 of 321 enrolled parti...
Research company Diamyd Medical reports an operating result of -127.2 million kronor (-48.1) for the third quarter of 2026.
On Wednesday reports are expected from the American stock rocket Micron and the Swedish crisis-stricken First North company Diamyd Medical.
The diabetes research company Diamyd Medical, after the results from the Diagnode-3 study, will prioritize an orderly winding down of the Phase 3 program. It appears...
Track Diamyd Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.